









Markets
/
Stocks
/
nasdaq-ormp
/

Oramed Pharmaceuticals Inc

ORMP

2.340USD

-0.100-4.10%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

95.58MMarket Cap

LossP/E TTM



Oramed Pharmaceuticals Inc

2.340

-0.100-4.10%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

215 / 506

Overall Ranking

345 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

3.250

Target Price

+36.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 19.06M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -3.94, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.94M shares, decreasing 6.07% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 144.20K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 9.09, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.09

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.82

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -4.11, which is -219.23% below the recent high of 4.90 and -13.77% above the recent low of -4.68.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 215/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Oramed Pharmaceuticals Inc is 3.25, with a high of 3.25 and a low of 3.25.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.77, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.57 and the support level at 2.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.77

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.015

Buy

RSI(14)

56.700

Neutral

STOCH(KDJ)(9,3,3)

54.870

Sell

ATR(14)

0.089

High Vlolatility

CCI(14)

103.092

Buy

Williams %R

43.243

Buy

TRIX(12,20)

0.453

Sell

StochRSI(14)

21.848

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.332

Buy

MA10

2.344

Sell

MA20

2.264

Buy

MA50

2.179

Buy

MA100

2.190

Buy

MA200

2.251

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 34.14%, representing a quarter-over-quarter decrease of 1.24%. The largest institutional shareholder is James Simons, holding a total of 144.20K shares, representing 0.35% of shares outstanding, with 6.61% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

3.02M

+14.25%

Kidron (Nadav)

2.02M

-4.54%

Shapiro (Benjamin)

1.96M

+1.80%

Murchinson Ltd.

1.75M

+0.05%

Boothbay Fund Management, LLC

845.49K

+0.04%

Hexter Joshua

812.17K

+18.51%

Kidron (Miriam)

781.33K

-0.87%

Rathbones Investment Management Limited

236.80K

-18.29%

Li (Xiaopeng)

218.60K

Dimensional Fund Advisors, L.P.

141.08K

+18.56%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.80, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.